Rallybio Corp
Research Rallybio Corp (RLYB) on Bullrun: market cap USD 89.61M, P/E 2.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRLYB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 89.61M
- P/E2.2
- Financial periodQ2 2026
- RevenueUSD 0
- Net incomeUSD 43.67M
- Free cash flowUSD 45.92M
Valuation Snapshot
latest market cap is USD 89.61M; P/E is 2.2.
Peer valuation comparison
Latest P/E is 2.16x versus a Healthcare sector median of 24.46x (91.2% below).
Latest P/E is 2.16x versus a United States median of 24.87x (91.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 858.00K | -USD 8.98M | -USD 29.81M | n/a | -1.59 | USD 31.37M | USD 176.00K | USD 57.96M |
| FY2024 | USD 636.00K | -USD 57.78M | -USD 49.28M | n/a | -10.61 | USD 13.90M | USD 154.00K | USD 61.65M |
| FY2023 | n/a | -USD 74.56M | -USD 60.28M | n/a | -1.84 | USD 24.49M | USD 392.00K | USD 106.18M |
| FY2022 | n/a | -USD 66.65M | -USD 57.34M | n/a | -2.09 | USD 56.96M | USD 628.00K | USD 169.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 89.61M | 2.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 28.99M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 39.85M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 90.33M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 248.60M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 306.52M | n/a | n/a | n/a |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rallybio Corp's market cap?
Rallybio Corp's market capitalization is USD 89.61M.
What is Rallybio Corp's P/E ratio?
Rallybio Corp's price-to-earnings (P/E) ratio is 2.2.
What does Rallybio Corp do?
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.